Summer News from MDRI


SUMMER GREETINGS!

sticky-note-Summer
We thought we’d reach out to you to wish you an enjoyable summer!
Here are some updates regarding some of the skin conditions we help treat:

Psoriasis

  • Risankizumab (an IL-23 inhibitor) has received FDA approval for the treatment of moderate-to-severe plaque psoriasis. We are proud to have been a part of these clinical trials and have you, our patients, to thank!
  • The FDA has also approved a new topical combination lotion — corticosteroid (halobetasol propionate) and a retinoid (tazarotene) for psoriasis.
  • The American Academy of Dermatology and the National Psoriasis Foundation have released joint guidelines on the treatment and management of psoriasis — with more to come. Our own Dr. Alan Menter is co-chair of these guidelines! Click for a short summary .

Atopic Dermatitis

  • Dupilimab is now approved for teenagers — as young as 12.
  • Looking for eczema friendly products? Click here for products that have received the National Eczema Association Seal of Acceptance.

Hidradenitis Suppurativa

Clinical Trials